key: cord-0969505-29vu33o9
authors: Papri, Nowshin; Hayat, Shoma; Mohammed, Asif; Afsar, Md. Nure Alam; Hasan, Imran; Rahman, Ananna; Jahan, Israt; Islam, Zhahirul
title: Guillain-Barré syndrome associated with SARS-CoV-2 infection: A case report with long term follow up
date: 2021-04-28
journal: J Neuroimmunol
DOI: 10.1016/j.jneuroim.2021.577590
sha: 63f26f662f76c033b4321caafe1d7f40844916d2
doc_id: 969505
cord_uid: 29vu33o9

A 50-years old male presented with quadriplegia and paresthesia and was diagnosed as Guillain-Barré syndrome (GBS). He was found positive for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) six weeks prior to the onset of weakness. GBS disability score was 4. Electrophysiology showed acute inflammatory demyelinating polyradiculopathy. Anti-SARS-CoV-2 IgG was found positive. Immunological tests for Campylobacter jejuni, Zika virus, Hepatitis E virus,Herpes Simplex virus, Haemophilus influanzae and Mycoplasma pneumoniae were negative. Patient received standard dose of intravenous immunoglobulin and after six months had almost complete recovery of muscle power. This case represents possible association of SARS-CoV-2 infection and GBS with good clinical outcome.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which causes coronavirus disease-2019 has affected around one hundred and two million people with more than two million mortalities all over the world, as of January 31, 2021 (Johns Hopkins University, 2021). COVID-19 predominantly causes mild to severe respiratory symptoms; however, multiple systemic manifestations have also been reported (Huang et al., 2020) .

Neurological manifestations due to COVID-19 have been reported among 40% of the patients which include headache, altered consciousness, acute encephalopathy, ataxia or peripheral nervous system involvement (Mao et al., 2020) . Numerous case-reports/series have been published which suggest a possible association between SARS-CoV-2 infection and Guillain-Barré syndrome (GBS) (Hasan et al., 2020; Uncini et al., 2020) . Observational multicenter studies in Italy reported 2.6-5.4 -fold increase in the incidence of GBS during the pandemic (Filosto et al., 2020; . Gigli et al., 2020) . However, most of these studies did not exclude the possibility of other common antecedent infections which have been evidenced to trigger the development of GBS. More recently, an epidemiological and cohort study in the UK concluded that GBS was not associated with COVID-19 (Keddie et al., 2020) . Therefore, it is still too early to rule out the association between SARS-CoV-2 infection and GBS. Moreover, the clinical outcome of these patients has not been thoroughly investigated. Hereby, we present a GBS case following SARS-CoV-2 infection with exclusion of other common antecedent events that may cause GBS. We also followed up the patients until six months of disease onset to evaluate the recovery pattern.

The patient was admitted to National Institute of Neurosciences and Hospital, Dhaka, Bangladesh on 3 September 2020. GBS was diagnosed as per National Institute of Neurological Disorders and Stroke (NINDS) criteria and confirmed by nerve conduction study (NCS). SARS-CoV-2 infection was confirmed by real-time reverse transcriptase-polymerase chain reaction (RT-PCR). Serological markers and routine laboratory investigations were performed by enzyme-linked immunosorbent assay (ELISA) and chemistry auto-analyzer respectively. We followed up the patient at week 2, week 8 and week 26.

On 3 rd September, 2020, a 50 years old hypertensive male presented with progressive symmetrical weakness of both upper and lower limbs for 12 days. He also had complaints of limb pain, mild paresthesia and constipation for 7 days. The patient had a history of flu like symptoms including cough and fever six weeks prior to the onset of weakness. Thereafter, he was tested for SARS-CoV-2 by RT-PCR of nasopharyngeal sample and found positive. Initially, he was managed at home with oral acetaminophen. A week later, he developed respiratory distress and was hospitalized where he was treated with oxygen therapy and antibiotic (ceftriaxone), other supportive treatments. After 5 days of hospitalization, he became clinically stable with subsiding respiratory distress and fever and was discharged from Covid unit to home.

During admission for quadriparesis at NINS, patient was found afebrile with normal vitals except blood pressure 144/99 mm Hg during clinical examination. All deep tendon reflexes were absent. (Table 1) .

The patient received standard dose (0.4 g/Kg per day for 5 days) of intravenous immunoglobulin (IVIg). On 8 th September, 2020 high resolution CT of chest was performed which showed involvement of both lungs having multifocal ground glass infiltrates, consolidations with fibrosis with total 42% lung involvement. RT-PCR for SARS-CoV-2 remained positive for comparatively longer duration and became negative on 18 th September, 2020, after eight weeks of onset of initial respiratory symptoms. After six months of onset of GBS, he has MRC sum score -5/5 (upper limb) and 4/5 (lower limb); GBS disability score was 1 with complaints of tingling sensation in both feet. Patient has resumed his usual daily activities with complaints of minor fatigue in sustained physical activity (Fig 1) .

We report a patient who was diagnosed as GBS with confirmed preceding SARS-CoV-2 infection. The clinical features along with NCS findings confirmed the diagnosis of GBS. The association of SARS-Cov-2 infection was confirmed through RT-PCR with serological affirmation of anti-SARS-CoV-2 IgG. The possibilities of other common antecedent infections that trigger the development of GBS were excluded. The patient was followed up at different time points and found good recovery after six months of disease onset.

Till date, more than 70 GBS cases from all over the world have been reported with a possible association with SARS-CoV-2 (Hasan et al., 2020; Uncini et al., 2020) . However, most of these cases were reported from western countries, around 80% from Europe (Uncini et al., 2020) . Very limited data are available on SARS-CoV-2-associated GBS from low-and middle-income countries except four cases from India, one from Morocco and one from Sudan (Hasan et al., 2020; Nanda et al., 2020; El Otmani et al., 2020; Sidig et al., 2020) . About 80% previously reported cases had electro-diagnostic features of demyelinating GBS and 62% showed definite improvement after treatment with IVIg which is consistent with current findings (Hasan et al., 2020; Uncini et al., 2020) . Antecedent infections predominantly respiratory or gastrointestinal symptoms are reported by two-thirds of patients with GBS. The most frequently identified infectious agents that triggers GBS are C. jejuni, CMV, Epstein-Barr virus, mycoplasma pneumonia and Zika (Wakerley et al., 2013) . SARS-CoV-2 is a very new viral infection and common complications along with the pathogenesis are not yet well established. In general, GBS is a post-infectious disorder which develops due to generation of auto-antibodies that cross react with specific nerve gangliosides J o u r n a l P r e -p r o o f Journal Pre-proof (van Den Berg et al., 2014) . However, anti-GM1antibody was negative in the current patient which was similar with previously reported cases (Uncini et al., 2020) .

The average period between antecedent infection with SARS-CoV-2 and the onset of GBS is usually 1-2 weeks. However, longer period up to 5 weeks has also been reported in recent study (Hasan et al., 2020) . In the current patient, the duration between the development of GBS and infection with SARS-CoV-2 was ~6 weeks. In general, the duration of onset of GBS and any antecedent events is usually considered as 1-4 weeks. But the maximum duration has been reported up to 6 weeks (Yuki et al., 2012) . The patient was found negative for other common antecedent infections except positive for CMV IgG antibody indicative of previous infection with CMV. In Bangladesh, CMV-IgG seroprevalence is 98% in healthy adult (Islam et al., personal communication) . Considering all these evidences, we cannot exclude SARS-Cov-2 infection as a possible causative agent of GBS in the current patient.

The current patient had positive RT PCR for SARS-CoV-2 even after 6 weeks of COVID-19 diagnosis although he was clinically recovered. This could be due to persistence of shedding of the virus or presence of virus residues in the host even after clearance of live virus which can persist after 20-44 days of active infection (Lan et al., 2020; He at al., 2020) .

This case report adds evidence that SARS-CoV-2 infection is associated with typical presentation of GBS, predominantly AIDP variant, that respond to standard IVIg treatment with a favorable outcome. Further case-control and cohort studies are required to evaluate the true causal relationship between SARS-CoV-2 and GBS. Figure 1 

El Mdaghri N, observational multicentre study from two Italian hotspot regions

Guillain-Barré syndrome in the COVID-19 era: just an occasional cluster

Guillain-Barré syndrome associated with SARS-CoV-2 infection: A systematic review and individual participant data meta-analysis

Positive RT-PCR Test Results in 420 Patients Recovered From COVID-19 in Wuhan: An Observational Study. Frontiers in pharmacology

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet

Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barré syndrome

Positive RT-PCR test results in patients recovered from COVID-19

Neurologic manifestations of hospitalized patients with coronavirus disease

Covid-19 associated Guillain-Barre Syndrome: contrasting tale of four patients from a tertiary care centre in India. The American journal of emergency medicine

COVID-19 and Guillain-Barre Syndrome-a Case

Guillain-Barré syndrome in SARS-CoV-2 infection: an instant systematic review of the first six months of pandemic

Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis

Infectious and noninfectious triggers in Guillain-Barré syndrome

Guillain-Barré syndrome

J o u r n a l P r e -p r o o f Journal Pre-proof icddr,b is grateful to its core donors including the Governments of Bangladesh, Canada, Sweden and the United Kingdom for providing core/unrestricted support for its operations and research.We thank Prof. Dr. Quazi Deen Mohammad for critically reviewing this manuscript.

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

The authors declare no competing interests. Z.I. received restricted grant (number 1K43TW011447-01) support from Fogarty International Center, the National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH) and Annexon Biosciences for activities unrelated to the subject matter of this paper.

Anti-HSV ( Type I + Type 2) IgM Negative